Subject: Repligen to Seek Approval For AIDS Vaccine Tests
Date: Published: 3/20/87 32 lines
Source:  Wall Street Journal.  Copyright Dow Jones & Co. Inc. 

   Repligen to Seek Approval
   For AIDS Vaccine Tests

   CAMBRIDGE, Mass. -- Repligen Corp. said it plans to file
an application with the Food and Drug Administration to begin
clinical tests on humans of a vaccine against acquired immune
deficiency syndrome.
   Repligen shares soared 28% in national over-the-counter
trading yesterday, closing at $26, up $5.75.
   The maker of biochemical products for industrial markets
is set to file the application with the agency in midsummer.
Repligen said it would like to begin testing the vaccine on
humans during the fall, if it receives FDA approval.
   The company is apparently only the second concern to seek
consent to begin testing an AIDS vaccine in humans.  On
Wednesday, Bristol-Myers Co. said its Oncogen subsidiary
plans to file a similar application with the FDA shortly,
also requesting consent to begin testing an AIDS vaccine in
humans.
   Repligen said its AIDS vaccine is a collaborative effort
with the National Cancer Institute and Duke University
Medical School.

(This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.)